

GENETHERA INC  
Form 8-K  
June 01, 2007

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) MAY 31, 2007

GENETHERA, INC.

(Exact name of registrant as specified in its charter)

FLORIDA

33-142603

65-0622463

(State or other  
jurisdiction

(Commission File Number)

(IRS Employer  
Identification No.)

of incorporation)

80033

Edgar Filing: GENETHERA INC - Form 8-K

3930 Youngfield Street,  
Wheat Ridge CO

(Zip Code)

(Address of principal  
executive offices)

Registrant's telephone number, including area code (303) 463-6371

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events**

GeneThera, Inc. issued a press release dated May 31, 2007 that GTI Corporate Transfer Agents, LLC (GTICTA) is processing the dividend previously announced, however, not all brokers have submitted the number of shares that they own in their accounts or the beneficial shareholders, tax id and/or social security numbers. GeneThera's transfer agency has previously requested this information from the brokerage firms for all shareholders as of record date May 21, 2007 in order to pay the dividend for each shareholder. Once GTICTA has received the information requested, the dividend will be processed for the shareholders accordingly.

**Item 9.01. Financial Statements and Exhibits.**

(d) The following exhibit is filed as part of this current report:

Exhibit 99.1      May 31, 2007 Press Release (Stock Dividend)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

May 31, 2007

GENETHERA, INC.

By: /s/ Tannya L. Irizarry

Tannya L. Irizarry

Chief Administrative Officer



Exhibit 99.1

## **GeneThera, Inc. s Transfer Agent Requesting Beneficial Shareholders List from Brokerage Firms**

Wheat Ridge, CO, May 31, 2007--MARKET WIRE--GeneThera, Inc. s (OTCBB: GTHA - News) transfer agency in charge of processing transfers, GTI Corporate Transfer Agents, LLC announced their request for the brokerage firms to provide GTHA beneficial shareholders list as of record date May 21, 2007 in order to pay the dividend for each shareholder. The brokerage firms must provide the shareholder s legal name, address, and tax id and/or social security number.

Information can be sent to GTI Corporate Transfer Agents, LLC, attention Ms. Laura Bryan at 3930 Youngfield Street, Suite Number 2, Wheat Ridge, CO 80033. The brokerage firm(s) can also choose to fax the data to the following number: 303/463-6377; if via electronically, please send it to [gticorporatetransfer@yahoo.com](mailto:gticorporatetransfer@yahoo.com).

If there are any inquiries, please contact Ms. Laura Bryan at the office 303/463-6375 from 9:00 a.m. to 5:00 p.m. Mountain Standard Time.

### About GeneThera, Inc.

GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, CO. The Company provides genetic diagnostic solutions for the veterinary and agricultural industries with future plans to include the health-care industry. The Company's proprietary diagnostic solution is based on a genetic expression assay, GEA, a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GEA is designed for a host of individual diseases, the current priority being Mad Cow Disease, Chronic Wasting Disease, a disease affecting elk and deer in North America; E.Coli 0157:H7 and Johnne's Disease, diseases affecting cattle worldwide.

Safe Harbor Statement: This News Release may include forward-looking statements within the meaning of section 27A of the United States Securities Act of 1933, as amended, and section 21E of the United States Securities & Exchange Act of 1934, as amended, with respect to corporate objectives, projections, estimates, operations, acquisition and development of various interests and certain other matters. These statements are made under the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements contained herein.

Contact:

GeneThera, Inc.

Tannya Irizarry, 303-463-6371

<http://www.genethera.net>